Long-Term Prospective Outcomes Of Patients With Non-Muscle Invasive Bladder Cancer Following Holmium Laser Ablation.

Darrad, Maitrey Padmasambhav and Syed, Jah and Ahmed, Zeba and Syed, Haider A (2019) Long-Term Prospective Outcomes Of Patients With Non-Muscle Invasive Bladder Cancer Following Holmium Laser Ablation. Journal of endourology / Endourological Society. ISSN 1557-900X. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

Full text not available from this repository.
Official URL: https://home.liebertpub.com/company/company-home/1...

Abstract

OBJECTIVES

To evaluate the long-term tumour recurrence, progression and cancer-specific mortality of patients following holmium laser ablation of non-muscle invasive bladder cancer (NMIBC) under topical anaesthesia. To identify variables that help to predict risk of tumour recurrence, progression and cancer-specific mortality.

MATERIALS & METHOD

A prospective study of 251 consecutive patients with 399 recurrent NMIBC who underwent outpatient Ho:YAG laser ablation under topical anaesthesia was carried out between September 2006 to September 2018. All patients underwent primary TURBT to obtain histology. All patients completed a patient satisfaction questionnaire and visual analogue scale (VAS) for procedure-related pain.

RESULTS

All 251 patients were analysed with an average age of 75.2 years and follow-up of 69.8 months. The majority of patients had multiple comorbidities with an ASA of 3 or 4. The proportion of tumour grade 1,2 & 3 disease and tumour stage Ta and T1 was 43.4%, 41.5%, 15.1%, 78.5% and 21.5% respectively. Overall 57.8% of patients had at least one tumour recurrence with an average time of 16.3 months. Risk factors were tumour grade, number of tumours at time of first laser ablation, and tumour stage. 19.1% of patients demonstrated tumour progression with an average time of 51 months. Only 5.6% of patients had progression to MIBC and the cancer specific mortality (CSM) rate was 5.2% with an average time to death of 71.2 months. Risk factors for CSM were tumour grade, stage, and patients age. The average VAS for pain was 0.6 out of 10 with all patients willing to have the procedure repeated if required.

CONCLUSION

Laser ablation of NMIBC is a safe, effective and well tolerated long-term option for patients, particular in those that have moderate to severe co-morbidities. The long-term cancer outcomes are best for younger patients with primary low grade and low stage disease.

Item Type: Article
Additional Information: This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects: WJ Urogenital system. Urology
Divisions: Planned IP Care > Urology
Related URLs:
Depositing User: Mrs Caroline Tranter
Date Deposited: 29 Aug 2019 13:49
Last Modified: 29 Aug 2019 13:49
URI: http://www.repository.uhblibrary.co.uk/id/eprint/2330

Actions (login required)

View Item View Item